Headache
| Migraine
Headache
Migraine
Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Co-administration with Preventive Monoclonal Antibody Treatment
book_2
Source:
AHSAM 2020 - Poster session
Published on July 17, 2020
calendar_today
Published on Medfyle:
June 2020
headphones
2
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Pharmacokinetic parameters of ubrogepant did not change following coadministration with erenumab or galcanezumab.
- There did not appear to be any safety concerns during coadministration with both erenumab and galcanezumab.
- The most common specific adverse event following study intervention was headache in 6 participants following erenumab injection.
Presenting Author
Author disclosures
Read more
arrow_downward
Hide
arrow_upward
Abhijeet Jakate, PhD: Allergan plc (Employment) (Stock Shareholder (excluding mutual funds), Salary)
